Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database

Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database. Am J Pathol. 2018 Jun 20. pii: S0002-9440(18)30129-9. doi: 10.1016/j.ajpath.2018.05.014. Moek KL, Fehrmann RSN, van der Vegt B, de Vries EGE, de Groot DJA. Abstract Glypican 3 (GPC3), a membrane-bound heparan sulfate proteoglycan, is…

Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma

Integrative kinome profiling identifies mTORC1/2 inhibition as treatment strategy in ovarian clear cell carcinoma. Clin Cancer Res. 2018 Apr 23. pii: clincanres.3060.2017. doi: 10.1158/1078-0432.CCR-17-3060. Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen A, Duiker EW, Weening D, Itamochi H, Kluin RJ, Reyners AKL, Birrer MJ, Salvesen…

Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma

Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma. Oral Oncology 2018; 80:33-39 Saskia H. Hanemaaijer, Stephanie E. van Gijn, Sjoukje F. Oosting, Boudewijn E.C. Plaat, Kirsten L. Moek, Ed M. Schuuring, Bernard F.A.M. van der Laan, Jan L.N. Roodenburg, Marcel A.T.M. van Vugt, Bert van der Vegt, Rudolf S.N. Fehrmann…

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach

Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. PLoS One. 2018 Feb 28;13(2):e0193098. doi: 10.1371/journal.pone.0193098. eCollection 2018. de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt M, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN#, van Meerten T#.…

Data driven prioritization and review of targets for molecular based theranostic approaches in pancreatic cancer

Data driven prioritization and review of targets for molecular based theranostic approaches in pancreatic cancer. J Nucl Med. 2017 Oct 19. pii: jnumed.117.198440. doi: 10.2967/jnumed.117.198440. [Epub ahead of print] # contributed equally Koller M, Hartmans E, de Groot DJA, Zhao XJ, van Dam GM, Nagengast WB#, Fehrmann RSN# Molecular targeted therapeutical and imaging strategies directed…

Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape

Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. ESMO Open; DOI: 10.1136/esmoopen-2017-000272 Sjoukje F Oosting, Rudolf S Fehrmann, Elisabeth G E de Vries In the Oxford dictionary, ‘Independent’ is defined as ‘Free from outside control; not subject to another’s authority’. Independence can be critical to identify important issues for patients. The…

The antibody-drug conjugate target landscape across a broad range of tumour types

The antibody-drug conjugate target landscape across a broad range of tumour types Annals of Oncology, mdx541, https://doi.org/10.1093/annonc/mdx541 K.L. Moek D.J.A. de Groot E.G.E. de Vries R.S.N. Fehrmann Background Antibody-drug conjugates (ADCs), consisting of an antibody designed against a specific target at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics.…

Theranostics Using Antibodies and Antibody-Related Therapeutics

Theranostics Using Antibodies and Antibody-Related Therapeutics. J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S. doi: 10.2967/jnumed.116.186940. Kirsten L. Moek, Danique Giesen, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Rudolf S.N. Fehrmann, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers and Elisabeth G.E. de Vries In theranostics, radiolabeled compounds are used to determine a treatment strategy…

Carlos Urzua joins the group

Carlos is a medical doctor from Mexico with good bioinformatical skills. So I’m very happy that Carlos with his rare combination of skills is joining our group. Carlos previously was a topmaster student in the Medical Pharmaceutical Drug Innovation (MPDI) topmaster at the University of Groningen / University Medical Center Groningen and worked in my…